TheStreet’s Action Alerts PLUS Portfolio Manager Jim Cramer was encouraged by the slew of drug approvals Valeant Pharmaceuticals received from the FDA, per an article from TheStreet’s Real Money team. ‘I’ve been negative on Valeant because
Subscribe to TheStreetTV on YouTube:
For more content from TheStreet visit:
Check out all our videos:
Follow TheStreet on Twitter:
Like TheStreet on Facebook:
Follow TheStreet on LinkedIn:
Follow TheStreet on Google+:
source
